Who
Richard C. Malabre
SVP, Chief Accounting Officer
Company insider
Files Form 4 as: SVP, Chief Accounting Officer, Akebia Therapeutics.
In numbers
- Trades disclosed
- 17
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $308K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 31 Jan 2024
- Last trade
- 2 Feb 2026
- Last filed
- 4 Feb 2026
Companies traded
Activity over time
1 Feb 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $50K36,142 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $19K13,382 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $50K36,142 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $19K13,382 at $1.39 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —79,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —119,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —119,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —79,000 at $0.00 | filing |
| 9 Jun 2025filed 11 Jun 2025 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 9 Jun 2025filed 11 Jun 2025 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $25K15,000 at $1.68 | filing |
| 9 Jun 2025filed 11 Jun 2025 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $60K15,000 at $4.01 | filing |
| 4 Jun 2025filed 5 Jun 2025 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $47K13,334 at $3.53 | filing |
| 3 Feb 2025filed 4 Feb 2025 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $63K30,202 at $2.10 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —128,000 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
| 31 Jan 2024filed 2 Feb 2024 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —336,000 at $0.00 | filing |
| 31 Jan 2024filed 2 Feb 2024 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —223,950 at $0.00 | filing |
News
Analyzing Akebia Therapeutics (NASDAQ:AKBA) and Pharming Group (NASDAQ:PHAR)AKBA · tickerreport.com · 18 Oct 2026Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health ForumAKBA · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Richard C. Malabre; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.